Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Quinidine-barbiturate | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Quinidine-barbiturate | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | | Quinidine-barbiturate | hsa00500 | Starch and sucrose metabolism | 2.86E-02 | 2 | O43451, P46976 | MGAM, GYG1 | More | | Quinidine-barbiturate | hsa00730 | Thiamine metabolism | 1.75E-04 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | Quinidine-barbiturate | hsa00770 | Pantothenate and CoA biosynthesis | 1.78E-02 | 2 | O95498, O95497 | VNN2, VNN1 | More | | Quinidine-barbiturate | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Quinidine-barbiturate | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Quinidine-barbiturate | hsa01240 | Biosynthesis of cofactors | 3.34E-02 | 3 | P05186, Q9Y6K8, O75911 | ALPL, AK5, DHRS3 | More | | Quinidine-barbiturate | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | | Quinidine-barbiturate | hsa04071 | Sphingolipid signaling pathway | 2.46E-03 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Quinidine-barbiturate | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Quinidine-barbiturate | hsa04120 | Ubiquitin mediated proteolysis | 6.89E-03 | 5 | Q14145, Q13042, Q13191, Q15751, Q7Z6Z7 | KEAP1, CDC16, CBLB, HERC1, HUWE1 | More | | Quinidine-barbiturate | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Quinidine-barbiturate | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Quinidine-barbiturate | hsa04612 | Antigen processing and presentation | 2.31E-04 | 9 | P13765, P48382, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Quinidine-barbiturate | hsa04613 | Neutrophil extracellular trap formation | 3.61E-02 | 13 | O60603, P05164, P08246, Q9UM07, Q6FI13, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Quinidine-barbiturate | hsa04621 | NOD-like receptor signaling pathway | 4.94E-03 | 13 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P59665, P59666, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Quinidine-barbiturate | hsa04640 | Hematopoietic cell lineage | 4.27E-02 | 4 | P08514, P14778, P01730, P13765 | ITGA2B, IL1R1, CD4, HLA-DOB | More | | Quinidine-barbiturate | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | | Quinidine-barbiturate | hsa04657 | IL-17 signaling pathway | 3.69E-03 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | Quinidine-barbiturate | hsa04658 | Th1 and Th2 cell differentiation | 1.12E-02 | 8 | Q04759, P20963, P09693, Q16539, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, STAT4, GATA3, TBX21, HLA-DOB | More | | Quinidine-barbiturate | hsa04659 | Th17 cell differentiation | 2.73E-02 | 4 | Q16539, P01730, P13765, P14778 | MAPK14, CD4, HLA-DOB, IL1R1 | More | | Quinidine-barbiturate | hsa04660 | T cell receptor signaling pathway | 3.76E-03 | 11 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, MAPK14, GSK3B | More | | Quinidine-barbiturate | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Quinidine-barbiturate | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Quinidine-barbiturate | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Quinidine-barbiturate | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Quinidine-barbiturate | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Quinidine-barbiturate | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Quinidine-barbiturate | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Quinidine-barbiturate | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Quinidine-barbiturate | hsa05032 | Morphine addiction | 1.09E-02 | 2 | P78334, P32298 | GABRE, GRK4 | More | | Quinidine-barbiturate | hsa05140 | Leishmaniasis | 1.87E-02 | 7 | P13612, O75015, P13765, O60603, P01375, Q16539, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, MAPK14, NCF4 | More | | Quinidine-barbiturate | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | | Quinidine-barbiturate | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Quinidine-barbiturate | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Quinidine-barbiturate | hsa05146 | Amoebiasis | 3.69E-03 | 9 | P09341, P19875, P27930, P01375, O60603, P05089, P30679, P22694, P08311 | CXCL1, CXCL2, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, CTSG | More | | Quinidine-barbiturate | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Quinidine-barbiturate | hsa05171 | Coronavirus disease - COVID-19 | 4.47E-02 | 2 | Q9UHA3, O14786 | RSL24D1, NRP1 | More | | Quinidine-barbiturate | hsa05202 | Transcriptional misregulation in cancer | 3.00E-02 | 13 | P14780, P27930, Q15744, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | | Quinidine-barbiturate | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Quinidine-barbiturate | hsa05310 | Asthma | 2.81E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Quinidine-barbiturate | hsa05321 | Inflammatory bowel disease | 2.16E-04 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Quinidine-barbiturate | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Quinidine-barbiturate | hsa05332 | Graft-versus-host disease | 1.36E-04 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Quinidine-barbiturate | hsa05340 | Primary immunodeficiency | 1.58E-02 | 3 | P01730, P11912, Q8WV28 | CD4, CD79A, BLNK | More | | |